Table 1.

Patient Demographics and Clinical Characteristics, Both for the Original Population of All Registered Patients and the Final Population of Patients Evaluable for the Primary End Point of Post-Treatment SUV Analyses

Demographic or Clinical Characteristic	All Patients Registered (N = 250)		Subgroup of Patients Evaluable for the Primary End Point (n = 173)
	No.	%	No.	%
Age, years
Median	65.5		65
Range	36-85		36-84
Race*
White	184	73.6	135	78.0
African American	29	11.6	15	8.7
Asian	32	12.8	22	12.7
Other/unknown	9	3.6	3	1.7
Clinical stage†
IIB	9	3.6	7	4.1
IIIA	123	49.2	96	55.5
IIIB	114	45.6	70	40.5
IV‡	1	0.4	0	0.0
Data not available	3	1.2	0	0.0
Sex
Male	162	64.8	112	64.7
Female	88	35.2	61	35.3
Performance status
0 (fully active)	111	44.4	84	48.6
1 (ambulatory, capable of light work)	137	54.8	89	51.5
Data not available	2	0.8	0	0.0
Chemotherapy regimen
Carboplatin/paclitaxel	102	40.8	73	42.2
Cisplatin/etoposide	36	14.4	29	16.8
Other	93	37.2	71	41.0
Data not available	19	7.6	0	0
Adjuvant (postradiotherapy) chemotherapy given
Yes	100	40.0	78	45.1
No	129	51.6	94	54.3
Data not available (unknown)	21	8.4	1	0.6
Radiation dose, Gy
< 50	10	4.0	0	0
50-60 Gy	11	4.4	8	4.6
60-70 Gy	153	61.2	124	71.7
≥ 70 Gy	56	22.4	39	22.5
Data not available	20	8.0	2	1.2

Abbreviation: SUV, standardized uptake value.

^*Multiple races may be endorsed by a single participant, such that the total over all options may sum to greater than 100%.

^†One patient with clinical stage recorded only as stage III was grouped into the stage IIIB row for both columns.

^‡One patient was enrolled with oligometastatic stage IV disease.